Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Vaccination Using an Allogeneic Leukemia-Derived Dendritic Cell Vaccine, Maintains and Improves Frequencies of Circulating Antigen Presenting Dendritic Cells Correlating with Relapse Free and Overall Survival in AML Patients

Hester Van Zeeburg, Eva Wagner Drouet, Uwe Platzbecker, Tobias A.W. Holderried, Catharina Van Elssen, Aristoteles Giagounidis, Soren Lehmann, Jeroen Rovers, Bjorn T. Gjertsen, Arjan A. van de Loosdrecht

Blood (2023) 142 (Supplement 1): 2957.

https://doi.org/10.1182/blood-2023-188573

Published: 2023

Journal Articles

Induction of Cellular and Humoral Immune Responses Is Associated with Durable Remissions in MRD+ AML-Patients after Maintenance Treatment with an Allogeneic Leukemia-Derived Dendritic Cell Vaccine

Arjan A. van de Loosdrecht, Eva Wagner Drouet, Uwe Platzbecker, Tobias A.W. Holderried, Catharina Van Elssen, Aristoteles Giagounidis, Soren Lehmann, Hester Van Zeeburg, Jeroen Rovers, Bjorn T. Gjertsen

Blood (2023) 142 (Supplement 1): 769.

https://doi.org/10.1182/blood-2023-185532

Published: 2023

Journal Articles

Intradermal Vaccination with Vididencel in MRD+ AML-Patients Leads to Increase in Antigen Presenting Cells and T-Cells to the Injection Site, Visualized Using Imaging Mass Cytometry, Showing Local Immune Cell Interactions Leading to Systemic Immune Responses

Oystein Sefland, Reidun Kristin Kopperud, Hester Van Zeeburg, Jeroen Rovers, Maria Omsland, Arjan A. Van de Loosdrecht, Bjorn T. Gjertsen

Blood (2023) 142 (Supplement 1): 2942.

https://doi.org/10.1182/blood-2023-180813

Published: 2023

Journal Articles

Use of an Allogeneic Leukemia-Derived Dendritic Cell Vaccine in MRD+ AML-Patients Results in MRD Conversion, Improved Relapse-Free Survival and Vaccine Induced Immune Responses to Tumor Antigens

Arjan A. Van de Loosdrecht, Jacqueline Cloos, Eva-Maria Wagner-Drouet, Uwe Platzbecker, Tobias A.W. Holderried, Catharina van Elssen, Aristoteles Giagounidis, Sören Lehmann, Hester J.T. van Zeeburg, Jeroen Rovers, Bjorn T. Gjertsen

Blood (2022) 140 (Supplement 1): 1714–1715.

https://doi.org/10.1182/blood-2022-162169

Published: 2022

Journal Articles

Induction of a Systemic Immune Response during Use of an Allogenic Leukemia-Derived Dendritic Cell Vaccine in MRD+ AML Patients Correlates with Clinical Response and MRD Conversion

Arjan A. Van de Loosdrecht, Jacqueline Cloos, Eva-Maria Wagner-Drouet, Uwe Platzbecker, Tobias A.W. Holderried, Catharina van Elssen, Aristoteles Giagounidis, Marij J.P. Welters, Sjoerd H. van der Burg, Hester J.T. van Zeeburg, Jeroen Rovers, Bjorn T. Gjertsen

Blood (2022) 140 (Supplement 1): 3410–3411.

https://doi.org/10.1182/blood-2022-163116

Published: 2022

Journal Articles

Treatment with an Allogeneic Leukemia-Derived Dendritic Cell Vaccine in AML Patients Shows MRD Conversion and Improved Survival

Arjan A. Van de Loosdrecht, Jacqueline Cloos, Eva Maria Wagner, Uwe Platzbecker, Tobias A. W. Holderried, Janine van Elssen, Aristoteles Giagounidis, Soren Lehmann, Hester van Zeeburg, Jeroen Rovers, Bjorn T. Gjertsen

Blood (2021) 138 (Supplement 1): 1274.

https://doi.org/10.1182/blood-2021-148333

Published: 2021

Journal Articles

Conversion from MRD Positive to Negative Status in AML Patients in CR1 after Treatment with an Allogeneic Leukemia-Derived Dendritic Cell Vaccine

Arjan van de Loosdrecht, MD PhD, Janine van Elssen, MDPhD, Bjørn Tore Gjertsen, Eva Maria Wagner, MD, Tobias Holderried, MD, Uwe Platzbecker, Jacqueline J Cloos, Jeroen Rovers, MD PhD

Blood (2020) 136 (Supplement 1): 13–14.

https://doi.org/10.1182/blood-2020-139266

Published: 2020

Journal Articles

Durable Responses and Survival in High Risk AML and MDS Patients Treated with an Allogeneic Leukemia-Derived Dendritic Cell Vaccine

Luca L.G. Janssen, MD, Theresia M. Westers, PhD, Jeroen Rovers, MD PhD, Peter Valk, PhD, Jacqueline Cloos, PhD, Tanja D. de Gruijl, PhD, Arjan A. Van de Loosdrecht, MD PhD

Blood (2019) 134 (Supplement_1): 1381.

https://doi.org/10.1182/blood-2019-127881

Published: 2019

Journal Articles

Donor Lymphocytes Depleted of Alloreactive T-Cells (ATIR101) Improve Event-Free Survival (GRFS) and Overall Survival in a T-Cell Depleted Haploidentical HSCT: Phase 2 Trial in Patients with AML and ALL

Denis-Claude Roy, MD, Silvy Lachance, MD, Jean Roy, MD, Irwin Walker, MBBS, Johan Maertens, MD PhD, Jean-Sebastien Delisle, MD PhD, Stephen Ronan Foley, MD, Philippe Lewalle, MDPhD, Eduardo Olavarria, Dominik Selleslag, MD, Manfred Rüdiger, PhD, Jurjen Velthuis, PhD, Lisya Gerez, Jeroen Rovers, MD PhD, Halvard Bonig, MD MA, Stephan Mielke, MD

Blood (2016) 128 (22): 1226.

https://doi.org/10.1182/blood.V128.22.1226.1226

Published: 2016

Journal Articles

Donor Lymphocytes Depleted of Alloreactive T-Cells (ATIR101) Reduce Transplant Related Mortality and Improve Overall Survival in Haploidentical HSCT for Patients with AML and ALL, Using an Immunosuppressant-Free Transplant Regimen

Denis-Claude Roy, MD, Silvy Lachance, MD, Jean Roy, MD, Irwin Walker, MBBS, Johan Maertens, MD PhD, Sandra Cohen, MD, Stephen Ronan Foley, MD, Philippe Lewalle, MD PhD, Eduardo Olavarria, MD PhD, Dominik Selleslag, MD, Manfred Rudiger, Jurjen Velthuis, PhD, Karen Reitsma, PhD, Lisya Gerez, Jeroen Rovers, MDPhD, Halvard Bonig, MD MA, Stephan Mielke, MD

Blood (2015) 126 (23): 4391.

https://doi.org/10.1182/blood.V126.23.4391.4391

Published: 2015

NARROW

Vaccination Using an Allogeneic Leukemia-Derived Dendritic Cell Vaccine, Maintains and Improves Frequencies of Circulating Antigen Presenting Dendritic Cells Correlating with Relapse Free and Overall Survival in AML Patients

Induction of Cellular and Humoral Immune Responses Is Associated with Durable Remissions in MRD+ AML-Patients after Maintenance Treatment with an Allogeneic Leukemia-Derived Dendritic Cell Vaccine

Intradermal Vaccination with Vididencel in MRD+ AML-Patients Leads to Increase in Antigen Presenting Cells and T-Cells to the Injection Site, Visualized Using Imaging Mass Cytometry, Showing Local Immune Cell Interactions Leading to Systemic Immune Responses

Use of an Allogeneic Leukemia-Derived Dendritic Cell Vaccine in MRD+ AML-Patients Results in MRD Conversion, Improved Relapse-Free Survival and Vaccine Induced Immune Responses to Tumor Antigens

Induction of a Systemic Immune Response during Use of an Allogenic Leukemia-Derived Dendritic Cell Vaccine in MRD+ AML Patients Correlates with Clinical Response and MRD Conversion

Treatment with an Allogeneic Leukemia-Derived Dendritic Cell Vaccine in AML Patients Shows MRD Conversion and Improved Survival

Conversion from MRD Positive to Negative Status in AML Patients in CR1 after Treatment with an Allogeneic Leukemia-Derived Dendritic Cell Vaccine

Durable Responses and Survival in High Risk AML and MDS Patients Treated with an Allogeneic Leukemia-Derived Dendritic Cell Vaccine

Donor Lymphocytes Depleted of Alloreactive T-Cells (ATIR101) Improve Event-Free Survival (GRFS) and Overall Survival in a T-Cell Depleted Haploidentical HSCT: Phase 2 Trial in Patients with AML and ALL

Donor Lymphocytes Depleted of Alloreactive T-Cells (ATIR101) Reduce Transplant Related Mortality and Improve Overall Survival in Haploidentical HSCT for Patients with AML and ALL, Using an Immunosuppressant-Free Transplant Regimen

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only